Tag Archives: NHS

UK Drug Pricing: An ICER of Zero?

by Leela Barham The incremental cost effectiveness ratio (ICER) – or the threshold for determining whether the costs of a new medicine are worth it – has been controversial since it’s inception. There are those who deny that anyone can put a price-tag on life; those that accept the concept but are happy to let […]
Posted in Europe, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , | Leave a comment

England: Is the Cancer Drugs Fund Running Out of Money?

By Leela Barham. The headlines have moved on for the English Cancer Drugs Fund (CDF). Replacing the positive press releases such as “thousands of patients to benefit” in 2013 are headlines shouting out that “thousands face being denied life-extending medication”.  In other words, a return to the same concerns that prompted the creation of the […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Also tagged , , , | 1 Comment

Bid to Improve Access to Medicines in Scotland

Access to new medicines: A new, improved, approach in Scotland By Leela Barham A major Inquiry into access to new medicines across Scotland by the Scottish Health and Sport Committee has come to an end. The Scottish Government has responded, and announced changes to how Scotland makes decisions on what new medicines to use across […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed | Also tagged , , | Leave a comment

England's Latest Innovation Scorecard: A Patchy Picture

By Leela Barham. A common gripe from those in the pharma industry in England is that even when their products have been found to be cost effective by the National Institute for Health and Care Excellence (NICE) (not always easy to do these days), uptake in the NHS can be ‘low and slow’.  The latest […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | Leave a comment

The UK's New "Revolutionary" Medicines Optimization Plan

By Leela Barham. The UK’s Royal Pharmaceutical Society has joined forces with a number of other organizations, including the Association of the British Pharmaceutical Industry (ABPI), to issue new guidance on medicines optimization.  Sir Bruce Keogh, Medical Director of NHS England, says it could be revolutionary.
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta